Cannabis could be deemed an successful treatment for patients living with multiple sclerosis according to research recently performed. Although at first the symptomatic changes encountered by cannabinoid-administered patients with multiple sclerosis were believed to be dictated primarily by psychological causes, subsequent studies discovered that cannabis significantly decreases muscle spasms and stiffness typical of multiple sclerosis sufferers. Do you want to learn more? Visit CBD South Africa. The beneficial effects of cannabis on patients with multiple sclerosis were confirmed by medical studies controlled over the short and long term.
The previous studies involved the active involvement of some 600 patients with advanced-stage multiple sclerosis. The patients were split into two distinctive groups : the first group obtained cannabinoid substances in equivalent amounts, while the second group collected placebo drugs over a 15 week span. At the conclusion of the trial, the bulk of patients given cannabinoids showed substantial symptomatic changes, reported reduced body discomfort, and had a milder muscle spasticity (reduced noticeable muscle spasm). By comparison to the community that obtained cannabinoid compounds during the research period, the control group (patients taking placebo medication) did not report any changes by their clinical health.
The study was subsequently replicated in order to affirm the validity of the results and to eliminate any concerns regarding the efficacy of cannabis in reducing the effects of multiple sclerosis. The ensuing research took place over a 12-month span, including the inclusion of the same topics. However, as in the case of the previous experiment, this time the participants were divided into 3 distinctive groups instead of 2. The first group got D9-tetrahydrocannabinol (THC) tablets-the active ingredient in cannabis, the second group received normal hemp extracts, whilst the third group received placebo
By the conclusion of the trial a team of physiotherapists and neurologists thoroughly analyzed and assessed the participants. Between the participants belonging to the first research category the highest outcomes were reported, with the number of respondents obtaining equivalent doses of THC witnessing substantial changes in their symptoms. The patients in the second research group reported mild differences in their symptoms, while the patients in the third group did not notice any changes in their condition.
Given the fact that such findings explicitly indicate that cannabis is an important cure for multiple sclerosis, medical science also aren’t persuaded that cannabinoids will be used effectively in multiple sclerosis care. Nevertheless, doctors can consider introducing cannabinoid compounds in the treatment of multiple sclerosis in the near future, after carrying out additional studies on the subject and more detailed analysis.